spbmedicalrecordsНовые Санкт-Петербургские врачебные ведомостиNew St. Petersburg Medical Records1609-2201Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова10.24884/1609-2201-2025-104-2-11-18spbmedicalrecords-88Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSДанные реальной клинической практики: основные дефиницииReal-world data: basic definitionshttps://orcid.org/0009-0002-6681-232XСвечкареваИ. Р.SvechkarevaI. R.

Изабелла Размиковна Свечкарева, ординатор кафедры клинической фармакологи и доказательной медицины

197022, Санкт-Петербург, ул. Льва Толстого, д. 6–8

Izabella R. Svechkareva,  resident of the department of Clinical Pharmacology and Evidence-Based Medicine

6–8, L’va Tolstogo str., Saint Petersburg, 197022

Bellaliza@yandex.ruhttps://orcid.org/0009-0001-2228-8565ВалееваА. Х.-М.ValeevaA. H.-M.

Валеева Алтынай Хаджи-Муратовна, ординатор кафедры клинической фармакологии и доказательной медицины

Санкт-Петербург

Altynai H.-M. Valeeva, resident of the department of Clinical Pharmacology and Evidence-Based Medicine  

Saint Petersburg

sovoglazka2000@yandex.ruhttps://orcid.org/0009-0003-4992-559XБушеваТ. И.BushevaT. I.

Бушева Татьяна Игоревна, ординатор кафедры клинической фармакологи и доказательной медицины

Санкт-Петербург

Tatiana I. Busheva, resident of the department of Clinical Pharmacology and Evidence-Based Medicine

Saint Petersburg

boushewa@mail.ruhttps://orcid.org/0000-0002-1919-2909КолбинА. С.KolbinA. S.

Колбин Алексей Сергеевич, доктор медицинских наук, профессор, заведующий кафедрой клинической фармакологии и доказательной медицины; профессор кафедры фармакологии медицинского факультета

Санкт-Петербург

Alexey S. Kolbin, Dr. of Sci. (Med.), Professor, Associate Professor, Department of Clinical Pharmacology and Evidence-Based Medicine; associate professor, Department of Pharmacology

St. Petersburg

Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. ПавловаРоссияPavlov UniversityRussian FederationПервый Санкт-Петербургский государственный медицинский университет имени академика И. П. ПавловаРоссияPavlov UniversityRussian FederationПервый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова; Санкт-Петербургский государственный университет, Медицинский институтРоссияPavlov University; St. Petersburg State UniversityRussian Federation202506112025021118Copyright © Свечкарева И.Р., Валеева А.Х., Бушева Т.И., Колбин А.С., 20252025Свечкарева И.Р., Валеева А.Х., Бушева Т.И., Колбин А.С.Svechkareva I.R., Valeeva A.H., Busheva T.I., Kolbin A.S.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.docved.ru/jour/article/view/88

Известным является тот факт, что с помощью анализа данных реальной клинической практики можно изучить актуальные вопросы системы здравоохранения и социального обеспечения, обобщить личный опыт пациентов, а также рассмотреть влияние медицинских технологий на различные исходы применения лекарственных препаратов, от клинических до социально-экономических.

It is well known that by analyzing data from real clinical practice, it is possible to study current issues in the health and social care systems, generalize the personal experiences of patients, and consider the impact of medical technologies on various drug outcomes, from clinical to socio-economic.

реальная клиническая практикаисточники данныхдоказательства на основе анализа данныхreal-world dataRWDdata sourcesreal-world evidenceRWEReferencesРешение Совета ЕЭК № 78 (ред. от 17.03.2022) «О внесении изменений в Правила регистрации и экспертизы лекарственных средств для медицинского применения». URL: https://docs.eaeunion.org/docs/ru-ru/01431480/err-18032022-36 (дата обращения: 10.07.2025).Decision of the EEC Council No. 78 (as amended on 17.03.2022) “On Amendments to the Rules for Registration and Expertise of Medicines for Medical Use”. URL: https://docs.eaeunion.org/docs/ru-ru/01431480/err-18032022-36 (accessed: 10.07.2025). (In Russ.).Framework for FDA’s Real-World Evidence Program. December 2018. URL: https://www.fda.gov/media/120060/download (accessed: 10.07.2025).Framework for FDA’s Real-World Evidence Program. December 2018. URL: https://www.fda.gov/media/120060/download (accessed: 10.07.2025).“Guiding Principles of Real-World Evidence supporting Drug Development and Review (Trial)” is formally promulgated by NMPA. URL: https://www.accestra.com/guiding-principles-of-real-world-evidence-supporting-drug-development-and-review-trial-is-formally-promulgated-by-nmpa/ (accessed: 10.07.2025).“Guiding Principles of Real-World Evidence supporting Drug Development and Review (Trial)” is formally promulgated by NMPA. URL: https://www.accestra.com/guiding-principles-of-real-world-evidence-supporting-drug-development-and-review-trial-is-formally-promulgated-by-nmpa/ (accessed: 10.07.2025).NICE real-world evidence framework, Corporate document. Published: 23 June 2022. URL: www.nice.org.uk/corporate/ecd9 (accessed: 10.07.2025).NICE real-world evidence framework, Corporate document. Published: 23 June 2022. URL: www.nice.org.uk/corporate/ecd9 (accessed: 10.07.2025).Jaksa A., Wu J., Jónsson P. et al. Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance // J. Comp. Eff. Res. 2021. Vol. 10, № 9. P. 711–731. https://doi.org/10.2217/cer-2020-0228.Jaksa A., Wu J., Jónsson P. et al. Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance. J. Comp. Eff. Res. 2021;10(9):711–731. https://doi.org/10.2217/cer-2020-0228.Honig P. K. Real-World Evidence and the Regulation of Medicines // Clin. Pharmacol. Ther. 2021. Vol. 109, № 5. P. 1169–1172. PMID: 33870489.Honig P. K. Real-World Evidence and the Regulation of Medicines. Clin. Pharmacol. Ther. 2021;109(5):1169–1172. PMID: 33870489.Haynes B. Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving // BMJ. 1999. Vol. 319, № 7211. P. 652–653. https://doi.org/10.1136/bmj.319.7211.652Haynes B. Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving. BMJ. 1999;319(7211):652–653. https://doi.org/10.1136/bmj.319.7211.652Cochrane A. L. Effectiveness and efficiency: random reflection on health services. London: Nuffield Provincial Hospitals Trust, 1972. https://doi.org/10.1016/S0033-3506(73)80082-4.Cochrane A. L. Effectiveness and efficiency: random reflection on health services. London: Nuffield Provincial Hospitals Trust, 1972. https://doi.org/10.1016/S0033-3506(73)80082-4.High Level Pharmaceutical Forum 2005–2008. Final Conclusions and Recommendations of the Pharmaceutical Forum. URL: http://www.bgpharma.bg/bulletin/read/edition/8/file/final_conclusions_en.pdf (дата обращения: 07.04.2020).High Level Pharmaceutical Forum 2005–2008. Final Conclusions and Recommendations of the Pharmaceutical Forum. URL: http://www.bgpharma.bg/bulletin/read/edition/8/file/final-conclusions-en.pdf (accessed: 07.04.2020).Управление клиническими исследованиями / под общ. ред. Белоусова Д. Ю., Зырянова С. К., Колбина А. С. 1-е изд. М.: Буки Веди: Издательство ОКИ, 2017. 676 с.: ил. URL: https://izdat-okiru/upravlenie-klinicheskimi-issledovaniyami (дата обращения: 07.04.2020).Clinical Trials Management / edited by Belousov D. Yu., Zyryanova S. K., Kolbin A. S. 1st ed. Moscow: Buki Vedi: OKI Publishing House, 2017. 676 p.: ill. URL: https://izdat-oki.ru/upravlenie-klinicheskimi-issledovaniyami (accessed: 07.04.2020). (In Russ.).Eichler H. G., Abadie E., Breckenridge A. et al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response // Nat. Rev. Drug. Discov. 2011. Vol. 10, № 7. P. 495–506. https://doi.org/10.2147/CLEP.S121991.Eichler H. G., Abadie E., Breckenridge A. et al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat. Rev. Drug. Discov. 2011;10(7):495–506. https://doi.org/10.2147/CLEP.S121991.Nordon C., Karcher H., Groenwold R. H. et al. The “Efficacy-Effectiveness Gap”: Historical Background and Current Conceptualization // Value Health. 2016. Vol. 19, № 1. P. 75–81.Nordon C., Karcher H., Groenwold R. H. et al. The “Efficacy-Effectiveness Gap”: Historical Background and Current Conceptualization. Value Health. 2016;19(1):75–81.Фармаконадзор / под общ. ред. Колбина А. С., Зырянова С. К., Белоусова Д. Ю. М.: Издательство ОКИ: Буки Веди, 2019. 248 с.: ил.Pharmacovigilance / edited by Kolbin A.S., Zyryanova S.K., Belousov D.Yu. M.: OKI Publishing House: Buki Vedi, 2019. 248 p.: ill. (In Russ.).Dijkstra L., Garling M., Foraita R., Pigeot I. Adverse drug reaction or innocent bystander? A systematic comparison of statistical discovery methods for spontaneous reporting systems // Pharmacoepidemiol. Drug. Saf. 2020. Vol. 29, № 4. P. 396–403. https://doi.org/10.1002/pds.4970.Dijkstra L., Garling M., Foraita R., Pigeot I. Adverse drug reaction or innocent bystander? A systematic comparison of statistical discovery methods for spontaneous reporting systems. Pharmacoepidemiol. Drug. Saf. 2020;29(4):396–403. https://doi.org/10.1002/pds.4970.Real-World Evidence Transparency Initiative. URL: https://www.ispor.org/strategic-initiatives/real-world-evidence/real-world-evidence-transparency-initiative (дата обращения: 20.04.2025).Real-World Evidence Transparency Initiative. URL: https://www.ispor.org/strategic-initiatives/real-world-evidence/real-world-evidence-transparency-initiative (accessed: 20.04.2025).EQUATOR. URL: https://www.equator-network.org/reporting-guidelines/ (дата обращения: 20.04.2025).EQUATOR. URL: https://www.equator-network.org/reporting-guidelines/ (accessed: 20.04.2025).The Editors Of The Lancet Group. Learning from a retraction // Lancet. 2020. Vol. 396, № 10257. P. 1056. https://doi.org/10.1016/S0140-6736(20)31958-9.The Editors Of The Lancet Group. Learning from a retraction. Lancet. 2020;396(10257):1056. https://doi.org/10.1016/S0140-6736(20)31958-9.Perez-Gutthann S., Arana A., Margulis A. ENCePP Guide on Methodological Standards in Pharmacoepidemiology. The current version of the Guide is Revision 10, dated 30 June 2022. URL: https://www.rtihs.org/publications/encepp-guide-methodological-standards-pharmacoepidemiology-10th-edition (accessed: 20.06.2025).Perez-Gutthann S., Arana A., Margulis A. ENCePP Guide on Methodological Standards in Pharmacoepidemiology. The current version of the Guide is Revision 10, dated 30 June 2022. URL: https://www.rtihs.org/publications/encepp-guide-methodological-standards-pharmacoepidemiology-10th-edition (accessed: 20.06.2025).Lavertu A., Vora B., Giacomini K. M. et al. A New Era in Pharmacovigilance: Toward Real-World Data and Digital Monitoring // Clin. Pharmacol. Ther. 2021. Vol. 109, № 5. P. 1197–1202. https://doi.org/10.1002/cpt.2172.Lavertu A., Vora B., Giacomini K. M. et al. A New Era in Pharmacovigilance: Toward Real-World Data and Digital Monitoring. Clin. Pharmacol. Ther. 2021;109(5):1197–1202. https://doi.org/10.1002/cpt.2172.Исследования реальной клинической практики. Обновленные рекомендации 2023 г. / под общей редакцией Колбина А. С. М.: Издательство ОКИ, 2023. 222 с. : ил. ISBN 978-5-907715-17-2.Research of real clinical practice. Updated recommendations of 2023 / edited by Kolbin A.S. Moscow: OKI Publishing House, 2023. 222 p.: ill. ISBN 978-5-907715-17-2. (In Russ.).

The authors declare that there are no conflicts of interest present.